Ablynx

From Wikipedia, the free encyclopedia

Ablynx is a biotech company located in Ghent, Belgium. The foundation of the company is based on the work of Raymond Hamers and his team at the Vrije Universiteit Brussel (Brussels, Belgium), who discovered a special type of antibodies, called Nanobodies.

[edit] History

The company was founded in 2002 with support from the Flanders Institute for Biotechnology (VIB), in collaboration with founding venture investor, GIMV

[edit] Source

• Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
• De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.
• Ablynx
• Ablynx technology rivals GSK's mini-antibodies
• Ablynx and Boehringer Ingelheim
• Flemish biotech spin-off, Ablynx, sets €75M IPO record

[edit] External links

• Ablynx